Safety and effectiveness of the transsubclavian approach for transcatheter aortic valve implantation with the 14-F CoreValve Evolut R device - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Journal of Cardiovascular Medicine Année : 2018

Safety and effectiveness of the transsubclavian approach for transcatheter aortic valve implantation with the 14-F CoreValve Evolut R device

Résumé

Aims - In addition to the transfemoral route, common approaches for transcatheter aortic valve implantation (TAVI) are the transapical and transaortic ones. Yet, these are associated with morbidity. The transsubclavian approach (TSA) is an alternative to minimize invasiveness. Methods - Fifteen consecutive patients underwent TAVI via TSA using the CoreValve Evolut R. The 14F delivery system without sheath was directly introduced into the artery. Results - Success was 100%; contrast volume was 99.4 ± 29.58 ml. Patients were extubated after 1.66 ± 0.89 h. Hemoglobin drop was 0.64 ± 0.28 g/dl. There were no complications. Hospital stay was 4.53 ± 1.24 days: 11 patients were discharged home, the remainder to rehabilitation. Conclusion - TSA is associated with limited morbidity, early patient mobilization, short hospitalization.
Fichier non déposé

Dates et versions

hal-01902638 , version 1 (23-10-2018)

Identifiants

Citer

Amedeo Anselmi, Jacques Tomasi, Francesco Giardinelli, Marc Bedossa, Sebastien Rosier, et al.. Safety and effectiveness of the transsubclavian approach for transcatheter aortic valve implantation with the 14-F CoreValve Evolut R device. Journal of Cardiovascular Medicine, 2018, 19 (11), pp.664-668. ⟨10.2459/JCM.0000000000000706⟩. ⟨hal-01902638⟩
33 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More